CRF receptor antagonists and methods relating thereto
AssigneeNeurocrine Biosciences, Inc.
InventorMustapha Haddach
Life of this patent
Estimating the term…
Abstract
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, R6, X and Y are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same
Claims18
A compound having the following structure:
- or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein:
- X is nitrogen or CR3;
- Y is nitrogen or CR4;
- R1 is alkyl, substituted alkyl, —NR7R8, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- R2 is hydrogen, alkyl, alkoxy, thioalkyl or haloalkyl;
- R3 is hydrogen, alkyl, halo or haloalkyl;
- R4 is hydrogen, halogen, —NR7R8, alkyl, alkoxy, thioalkyl or haloalkyl;
- R5 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- R6 is hydrogen, alkyl, substituted alkyl, —NR7R8, —OR9, —SR9, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- R7 and R8 are the same or different and independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- and
- R9 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl.
Dependencies are inferred from the claim text.